BCL-XL is an actionable target for treatment of malignant pleural mesothelioma (original) (raw)

Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy

Elena Varin

Carcinogenesis, 2010

View PDFchevron_right

Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma

Nilanjan Chaudhuri

Acta Oncologica, 2006

View PDFchevron_right

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

Surein Arulananda

Cell Death Discovery, 2021

View PDFchevron_right

Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma

Michael Jaklitsch

2002

View PDFchevron_right

Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis

Ralph Schmid

Cell Death & Disease, 2021

View PDFchevron_right

Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy

Yasser Bustanji

Biomolecules & therapeutics, 2024

View PDFchevron_right

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

C. Herold-mende

Oncogene, 2008

View PDFchevron_right

What can we learn from mice lacking pro-survival BCL-2 proteins to advance BH3 mimetic drugs for cancer therapy?

Ashley Ng

Cell Death & Differentiation, 2022

View PDFchevron_right

An inhibitor of Bcl2 family proteins induces regression of solid tumours

Letai Le

Nature, 2005

View PDFchevron_right

BCL-2 protein family: attractive targets for cancer therapy

deeksha kaloni

Apoptosis

View PDFchevron_right

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo

Yulian Ramirez, Mike-Andrew Westhoff

Oncotarget, 2015

View PDFchevron_right

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Karen Williams

Molecular Cancer Therapeutics, 2013

View PDFchevron_right

MCL-1 is a key determinant of breast cancer cell survival: Validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor

George Sheppard

Molecular cancer therapeutics, 2015

View PDFchevron_right

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

Nadege Gitego

Nature Communications, 2022

View PDFchevron_right

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers

Eugene Lifshits

Cancer research, 2014

View PDFchevron_right

Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer

Brona Murphy

Experimental oncology, 2012

View PDFchevron_right

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell Lung Cancer

Faria Siddiqui

Cancer Discovery

View PDFchevron_right

Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives

Mohamed Rahmani

Cancers, 2021

View PDFchevron_right

Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade

Violeta Jazmin Forneron Sanchez

Molecular cancer research : MCR, 2016

View PDFchevron_right

Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl2 and Bax in inflammatory and malignant pleural lesions

Antonio Marchetti

Lung Cancer, 2005

View PDFchevron_right

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

maricela ramirez

Cell death & disease, 2018

View PDFchevron_right

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Surein Arulananda

Cell Death & Disease, 2019

View PDFchevron_right

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

youngchul song

Cancer Cell, 2013

View PDFchevron_right

Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer

Anton-Scott Goustin

Recent patents on anti-cancer drug discovery, 2008

View PDFchevron_right

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Nghi La, Lisa Belmont, Wayne Fairbrother

Science translational medicine, 2015

View PDFchevron_right

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight

Ralph Schmid

Frontiers in Oncology, 2020

View PDFchevron_right

Knockdown of COPA, Identified by Loss-of-Function Screen, Induces Apoptosis and Suppresses Tumor Growth in Mesothelioma Mouse Model

Masakazu Kohda

Genomics, 2010

View PDFchevron_right

RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Insights into Novel Drugs Targeting Bcl-2 Protein as Potential Anti- cancer Agents

safaa kishk

2020

View PDFchevron_right

Cisplatin Resistance in Malignant Pleural Mesothelioma

Parviz Behnam-motlagh

Mesotheliomas - Synonyms and Definition, Epidemiology, Etiology, Pathogenesis, Cyto-Histopathological Features, Clinic, Diagnosis, Treatment, Prognosis, 2012

View PDFchevron_right

Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2

Zaneta Nikolovska-Coleska

Cancer Research, 2004

View PDFchevron_right

Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells

Hung Pham

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2013

View PDFchevron_right

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

Martin Dyer

Cell Death & …, 2008

View PDFchevron_right

Anti-apoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity

Rens Braster

Blood, 2014

View PDFchevron_right

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Erick Morris

Oncotarget, 2018

View PDFchevron_right